Founded in 2006 and headquartered in Salt Lake City, KURU Footwear centers its business on KURUSOLE, a patented triple-layer adaptive heel-cupping system designed to preserve the heel’s fat pad while providing targeted arch support and shock absorption. The company operated as a largely bootstrapped, direct-to-consumer brand for nearly two decades, achieving roughly 10–15% organic annual growth prior to the Series A and notable case-study metrics (715% transaction growth and 794% revenue growth in earlier periods). KURU has built clinical endorsement from podiatrists who recommend its shoes for heel pain and plantar fasciitis, supporting its credibility in the therapeutic footwear market. With the Series A proceeds, KURU plans to expand product lines (including men’s and athletic subcategories), accelerate marketing, and enter international DTC markets while building podiatrist referral programs. Financially, the company leveraged strong retention dynamics and direct distribution to demonstrate unit economics attractive to institutional investors.

Total raised

$12M

Funding rounds

1

Latest round

Series A

Latest activity

May 2026